David Pereyra

MD-PhD | General Surgery Resident | TELL International| Medical University of Vienna | Postoperative Liver Regeneration | Liver Transplantation

[Annals of Surgery @AnnalsofSurgery]

Forget costly liver tests. 💸 This large study shows an APRI+ALBI model accurately predicts liver failure after resection—and it’s free, fast, and now app-based.
🔗https://t.co/7437nhKdO2

[Nina Pilat @ninapilat]

Join us next Monday May 5th for the next #professionaldevelopment workshop "The researcher’s toolkit: building projects, securing grants and maximising impact"
@ESOTtransplant
@FrankaMessner
@lisetpengel
https://t.co/vvYsBBBI3J

[David Pereyra @TELLpereyra]

@gygdoc @OrganAssist @MedUni_Wien
#OrganPreservation #MachinePerfusion #Transplantation #MedicalEducation #SpringSchool #Vienna #XVIVO #FKöhlerChemie

[David Pereyra @TELLpereyra]

🫵 Join us in Vienna for this year's Spring School on Abdominal Organ Preservation!
✅ Extensive hands-on training in multi-organ retrieval
✅ Small groups for personalised learning
✅ Expert-led sessions on liver & kidney perfusion
✅ Latest scientific advancements in the field

[Fabian Eibensteiner @FabianEibenste1]

🚨 Exciting webinar: Biomarker in pediatric TX by @ESOTtransplant & @IptaPedsTx
Amazing speakers @olivieraubert_ & Michael Oellerich
🗓️ 26 Nov
🕕 16-17 CET
Register now https://t.co/hp8F4bvSA2
#ESOT_BasicScience
@evgenia_preka @ninapilat @kaisar_maria @caterina_lonati @So_Limou

[Journal of Hepatology @JHepatology]

🆕Article in press❕

Assessment of liver graft quality during hypothermic oxygenated perfusion

➡️The first international validation study

DOI👉https://t.co/wkiM8jlJuV

#LiverTwitter

[MedUni Wien @MedUni_Wien]

Advanced #liverdisease is the second most common cause of lost working years. A #MedUniVienna team has identified a threshold for a simple blood test that can identify people at increased risk of complications without special testing. ➡️ https://t.co/VZySzW3SpF

@JHepatology

[David Pereyra @TELLpereyra]

🫵👀 Join us for our Vienna Summer School on Hypothermic Machine Perfusion which is conducted in association with @OrganAssist ! Enjoy up-to-date lectures paired with hands-on workshops during this two day course. Secure your spot now! 🧠🔬#SummerSchool2024 #HypothermicPerfusion

[Patrick Starlinger_TELL International @TELL_Starlinger]

Congrats to the team of TELL!
With a total of 12 talks, multiple awards and grants with a total of 32.000,- € of support from the Austrian Society of Surgery, we are concluding the 2024 Annual meeting of the Austrian Society of Surgery. Increadibly proud of the team #MayClinic

[Benjamin Chan @DoctorBenChan]

Vienna 🇦🇹, to Maastricht 🇳🇱, to Liverpool 🏴󠁧󠁢󠁥󠁮󠁧󠁿, to Mayo Rochester 🇺🇸, and now Cape Town 🇿🇦 #IHPBA24.

Thank you @IHPBA for bring us together, and our mentors Patrick Starlinger, Stephen Fenwick, and Ronald van Dam.

[EASLnews @EASLnews]

@sapisochin in a State-of-the-art session at #LiverCancerSummit 2024 on "Rethinking the limits of liver transplantation for liver cancer." ⭐️

- Transplantation offers the best chance for long-term survival in select patients with liver cancer, especially those meeting the Milan criteria.

- Data shows over 80% 5-year survival and 12+ year median survival for patients transplanted within Milan criteria.

- With newer locoregional therapies and systemic therapies all patients eligible for transplants without extrahepatic disease should be considered in "downstaging protocols". Treatment response is key and clinical trials are needed.

- We urgently need better biomarkers to understand tumour biology.

- Patients with iCCA might benefit from Liver transplantation - more research is needed!

Exciting to see evidence that criteria could be expanded to help more patients battling liver cancer gain long-term survival through transplantation.💪🏻

[Journal of Hepatology @JHepatology]

🆕Expert Opinion❕

Merits and boundaries of the Barcelona Clinic Liver Cancer Staging and Treatment Algorithm

➡️Learning from the past to improve the future with a novel proposal

Read it here👉https://t.co/XFueXsqYwC

#LiverTwitter

[BJS @BJSurgery]

Comparing the accuracy of prediction models to detect clinically relevant post-hepatectomy liver failure early after major hepatectomy
➡️ https://t.co/Ohqe4SHFs7

Arterial lactate measurements were recently suggested as an early predictor of clinically relevant post-hepatectomy liver failure (PHLF), but in the subgroup of major liver resections a more comprehensive approach is needed.
1⃣In a cohort of 649 major hepatectomy patients, lactate on postoperative day (POD) 1 (AUC 0.75) was outperformed by both clinical risk factors (AUC 0.81, P < 0.05) and bilirubin POD1 (AUC 0.83, P < 0.05) in predicting clinically relevant PHLF grade B/C as defined by the International Study Group of Liver Surgery (ISGLS).
2⃣A multivariable logistic regression model including five clinical risk factors and bilirubin POD1 (AUC 0.87 (P < 0.01)) was developed to predict PHLF grade B/C in major hepatectomy already on POD1, with an equally good discriminatory potential for 90-day mortality as the established ISGLS criteria.

Great work by Ruth Baumgartner, Jennie Engstrand, Patric Rajala, Jonathan Grip, Poya Ghorbani, Ernesto Sparrelid, Stefan Gilg

#SoMe4Surgery #MedTwitter #SurgEd #Surgery #some4hpb #some4tpl @DPCG_official @pancreatitis_nl @P_C_E_ @dice_europe @BJSAcademy @young_bjs

[HEPATOLOGY Journal @HEP_Journal]

#HEP_highlights Etiological Treatment of Decompensated Cirrhosis: Is It Worthwhile?
Tonon L, Balcar L et al. In patients with cirrhosis and ascites as single first decompensating event, the cure of liver disease etiology represents a main treatment goal
https://t.co/B7qJha7HVy

[Giovanni Marchegiani @Gio_Marchegiani]

Liver transplant for colorectal cancer mets 😱 long term results from 🇳🇴

🧍‍♂️61 pts with non resectable CRLM in 14 years

👍 Predictor of outcomes were tumor size, CEA, number of lesions

🔟 year survival of 90% for Oslo score 0

🏔️ A new milestone ?!

https://t.co/gwu2nVCpoC

[Patrick Starlinger_TELL International @TELL_Starlinger]

Extremely proud of our group members Jonas Santol and Anna Kern that had their ILC - #EASL talks yesterday - immensely impressed by their presentation and discussion, despite being just in the first year of residency and Anna ever still in medical school - so much more to come !

[Patrick Starlinger_TELL International @TELL_Starlinger]

3 recent conferences - remarkable performance of TELL with a total of &gt; 15 talks (crazy - all new data) and 2 awards - incredibly proud of the team - amazing performance - now off to EASL for even more entertainment - go #TELL @TELL_Santol @TELLpereyra

[David Pereyra @TELLpereyra]

#TELLinternational @ Austrian Surgery Conference #ÖCK2023 : 12 orals, 1 poster, 2nd price in the #YoungSurgeonsForum 🌟

Amazed and proud about our performance as a group! Success is a team effort!

@YoungSurgeonsAT @oefnerdi @TELL_Starlinger @TELL_Santol @TELLRumpf @TELL_kern

[Giovanni Marchegiani @Gio_Marchegiani]

Piperacillin-Tazobactam 🤜🤛 Cefoxitin as prophylaxis for pancreatoduodenectomy

🇺🇸🇨🇦 RCT 778 patients

🪲 Pip-Taz reduced 30-day postoperative surgical site infection (32% vs. 20%), sepsis and POPF

⛳️ Practice changing evidence! Kudos to authors

https://t.co/61fp1eRcoa

[Patrick Starlinger_TELL International @TELL_Starlinger]

Quite excited about this picture - #AHPBA and #MayoClinic bringing together residents from all over the world - Rochester, Arizona, Austria and Italy - thx @drsuswarner and @Seanpcleary for setting up this great social event to also foster future collaborations and friendship